Noninterventional retrospective study of standard-of-care systemic treatment patterns and outcomes in US patients with advanced urothelial carcinoma
Our findings contribute to our understanding of optimal treatment sequencing options based on individual patient characteristics in a rapidly evolving treatment landscape.
Authors
- Chai Kim
- Sheena Thakkar (ORCID: https://orcid.org/0000-0002-7374-9130)
- Benjamin Li (ORCID: https://orcid.org/0000-0002-1783-7013)
- Anup Abraham
- Anna Vlahiotis
- Sanjana Chandrasekar
- Chiemeka Ike (ORCID: https://orcid.org/0000-0001-6309-6458)
- Melissa Kirker
- Darrin Benjumea
- Mairead Kearney
- Haiyan Sun (ORCID: https://orcid.org/0000-0001-5498-8251)
- Abhijeet Bhanegaonkar
- Helen Moon (ORCID: https://orcid.org/0009-0007-6303-5285)
Institutions
- Merck KGaA, Darmstadt (Germany) (DE)
- Pfizer (United States) (US)
- Merck Serono S.A. (Switzerland) (CH)
- Kaiser Permanente Riverside Medical Center (US)
- Genesis Research Institute (JP)
- Merck Serono S.p.A. (Italy) (IT)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1093/oncolo/oyaf071
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Merck